Keyphrases
Inflammatory Bowel Disease
100%
Crohn's Disease
99%
Ulcerative Colitis
44%
Israeli
36%
Israel
34%
Stress Fracture
26%
Infliximab
25%
Extractable Protein
25%
Oral Administration
23%
Basic Training
22%
Colon
22%
Clinical Remission
18%
Young Men
18%
Odds Ratio
16%
Immune Regulation
16%
Colitis
15%
Bone Mineral Density
15%
Phase I Clinical Trial
15%
Active Ulcerative Colitis
15%
Iron Deficiency
12%
Randomized Placebo-controlled Trial
12%
Adverse Events
12%
Body Mass Index
12%
Confidence Interval
12%
Emergency Department
12%
Military Recruits
11%
Army
11%
Quality of Life
11%
Tertiary Care Hospital
11%
Hospitalization
11%
Triglyceride Level
11%
Perianal Crohn's Disease
11%
Clinical Response
11%
Israel Defense Forces
10%
Adverse Neonatal Outcome
10%
Placental Histopathological Lesions
10%
Retrospective Cohort Study
10%
Remission Induction
10%
Celiac Disease
10%
Abdominal
10%
Diabetic Patients
10%
Population-based Study
10%
Fistula
10%
Cost-effectiveness
10%
Endocannabinoids
10%
Remission
10%
Disability
9%
Female Combatants
9%
Inflammation
9%
Cytomegalovirus
9%
Medicine and Dentistry
Crohn's Disease
55%
Inflammatory Bowel Disease
43%
Ulcerative Colitis
40%
Diseases
36%
Patient with Inflammatory Bowel Disease
33%
Prevalence
26%
Stress Fracture
25%
Patient with Crohn's Disease
24%
Clinical Trial
16%
Placebo
15%
Fistula
12%
Colon
12%
Odds Ratio
12%
Maturity Onset Diabetes of the Young
11%
Biological Product
10%
Oral Drug Administration
10%
Adverse Event
10%
Retrospective Cohort Study
10%
Emergency Department
10%
Pediatrics
10%
Computer Assisted Tomography
10%
Cost-Effectiveness Analysis
10%
Endoscopic Ultrasound
10%
Coeliac Disease
10%
Immunoregulation
10%
Infusion
10%
Infliximab
10%
Triacylglycerol
9%
Stricture
8%
Diabetes
8%
Randomized Controlled Trial
8%
Isotopes of Calcium
8%
Iron Deficiency
7%
Body Mass Index
6%
Quality of Life
6%
Colitis
6%
Diagnostic Test
6%
Patient Referral
6%
Diarrhea
5%
Recurrent Disease
5%
Infection
5%
Bloodstream Infection
5%
Maintenance Therapy
5%
Diagnostic Accuracy
5%
Bone Remodeling
5%
Serositis
5%
Colonoscopy
5%
Liver Disease
5%
Anemia
5%
Systematic Review
5%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
69%
Ulcerative Colitis
48%
Inflammatory Bowel Disease
45%
Remission
27%
Clinical Trial
27%
Infliximab
25%
Placebo
19%
Colitis
18%
Diseases
17%
Adverse Event
15%
Inflammation
13%
Side Effect
13%
Infection
11%
Diabetes Mellitus
10%
Population Study
10%
Endocannabinoid
10%
Cytomegalovirus
9%
Antioxidant
8%
Biological Product
8%
Prevalence
8%
2,4,6-Trinitrobenzenesulfonic Acid
7%
Mouse Model
7%
Retrospective Study
7%
Liver Disease
7%
Mercaptopurine
6%
Experimental Colitis
6%
Antivirus Agent
6%
Cytomegalovirus Infection
6%
Disease Activity
5%
Diarrhea
5%
Recurrent Disease
5%
Bloodstream Infection
5%
Enteritis
5%
Non Insulin Dependent Diabetes Mellitus
5%
Ustekinumab
5%
Vedolizumab
5%
Anus Fissure
5%
Colon Carcinoma
5%
Ciclosporin
5%
Tofacitinib
5%
Phase II Trials
5%
Prehypertension
5%
Etrolizumab
5%
Colon Tumor
5%
Coeliac Disease
5%
Gluten
5%
Protein A
5%
Chronic Hepatitis C
5%
Hepatic Encephalopathy
5%
Kitten
5%
